Pharmaceutical compositions include heteroaromatic compounds having a disease-modifying action in the treatment of fungal infections and diseases associated with fungal infection.

Pharmaceutical compositions include heteroaromatic compounds having a disease-modifying action in the treatment of fungal infections and diseases associated with fungal infection.

New compounds of formula I are described:

##STR00001##

The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.

New compounds of formula I are described:

##STR00001##

The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.

New classes of thiadiazole and oxadiazole compounds for use in LC mixtures are disclosed. In an embodiment, the new classes of thiadiazoles and oxadiazoles comprise at least one phenyl ring attached to the heterocyclic ring, where no alkyl, alkenyl or alkynyl tails are attached to the phenyl ring, but one alkyl, alkenyl or alkynyl tail is attached to the other end of the molecule, and a fluoro or cyano group appears in the para position of the phenyl ring. These compounds are disclosed as being effective at inducing smectic A phases in liquid crystal mixtures, particularly in liquid crystal mixtures also possessing a smectic C phase, more particularly in materials possessing a chiral smectic C (ferroelectric) phase.

New classes of thiadiazole and oxadiazole compounds for use in LC mixtures are disclosed. In an embodiment, the new classes of thiadiazoles and oxadiazoles comprise at least one phenyl ring attached to the heterocyclic ring, where no alkyl, alkenyl or alkynyl tails are attached to the phenyl ring, but one alkyl, alkenyl or alkynyl tail is attached to the other end of the molecule, and a fluoro or cyano group appears in the para position of the phenyl ring. These compounds are disclosed as being effective at inducing smectic A phases in liquid crystal mixtures, particularly in liquid crystal mixtures also possessing a smectic C phase, more particularly in materials possessing a chiral smectic C (ferroelectric) phase.

Disclosed is a class of dendrimers containing cyclometalated tridentate platinum(II) compounds with one monoanionic auxiliary ligand, both coordinated to a platinum (II) metal center and having the chemical structure shown in generic formula (I), wherein at least one of R.sub.1, R.sub.2 and R.sub.3 being a dendrimeric moiety of general formula (II), each being optionally substituted.

##STR00001##

Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds have the following structure:

##STR00001##

in which Z is an oxadiazole. The compounds disclosed are useful in treatment of fibrotic disease, particularly renal fibrosis, and similar diseases associated with the dysregulation of the HIPK2/Smad3 signaling pathway.

Disclosed are compounds of formula (I) below and pharmaceutically acceptable salts thereof, in which each of variables R.sub.1, R.sub.2, L, and Z is defined herein. Also disclosed are methods for reducing the glycemic level and treating glucagon-associated disorders with a compound of formula (I) or a salt thereof and a pharmaceutical composition containing same.

The present disclosure relates to compounds of formula (I) that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.

##STR00001##